@misc{oai:repo.qst.go.jp:00083860,
 author = {Kuan, Hu and 謝, 琳 and 張, 一鼎 and 破入, 正行 and 張, 明栄 and Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Zhang, Ming-Rong},
 month = {Nov},
 note = {Objectives
Integrin α5β1 is considered one of the most prominent targets among RGD binding integrin receptors for tumor diagnosis. Our goal is to develop a peptide-based radiotracer for PET imaging of α5β1-integrin in different types of cancers.

Methods
A peptide, with a sequence of KSSPHSRN(SG)5RGDSP (PR_b), was conjugated with a PEG molecule to obtain [64Cu]PEG-PR_b. PET imaging was performed in tumor-bearing mice. Ex vivo biodistribution and immunohistochemistry were employed to study the metabolism and specificity of the tracer.

Results
PET imaging revealed a higher tumor uptake of [64Cu]PEG-PR_b than that of [64Cu]PR_b (3.5%ID/g versus 1.8%ID/g) at 1 hour postinjection. Ex vivo biodistribution indicated that PEGylation delayed the kidney clearance of the tracers.

Conclusion
We anticipated clinical applicability of [64Cu]PEG-PR_b for imaging of α5β
1 by PET., 第61回日本核医学会学術総会},
 title = {In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide},
 year = {2021}
}